Suchergebnisse - "Monnet, Annabelle"

PubPharm (20)

1

Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's disease

enthalten in: Nature medicine | 2024

von Pagano, G. | Taylor, K. | Anzures Cabrera, J. | +17

2

Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson’s disease

enthalten in: ResearchSquare.com | 2024

von Pagano, G. | Taylor, K. | Cabrera, J. | +15

3

Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial

enthalten in: ResearchSquare.com | 2024

von Pagano, G. | Monnet, A. | Reyes, A. | +17

4

Exploratory Sensor-based Outcome Measures Show Divergent Slopes of Motor Sign Progression in Parkinson’s Disease Patients Treated with Prasinezumab

enthalten in: ResearchSquare.com | 2024

von Taylor, K. | Lipsmeier, F. | Scelsi, M. | +18

5

Trial of Prasinezumab in Early-Stage Parkinson's Disease

enthalten in: The New England journal of medicine | 2022

von Pagano, G. | Taylor, K. | Anzures-Cabrera, J. | +144

CommentIn: N Engl J Med. 2022 Aug 4;387(5):466-467. - PMID 35921458

6

Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia : Results from an idasanutlin phase 1/1b study⋆

enthalten in: Leukemia research | 2021

von Yee, K. | Papayannidis, C. | Vey, N. | +20

7

MIRROS : a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia

enthalten in: Future oncology (London, England) | 2020

von Montesinos, P. | Beckermann, B. | Catalani, O. | +14

8

Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion-With an application to the design of a clinical trial in acute myeloid leukemia

enthalten in: Pharmaceutical statistics | 2020

von Rufibach, K. | Heinzmann, D. | Monnet, A.

9

Integrating phase 2 into phase 3 based on an intermediate endpoint while accounting for a cure proportion—With an application to the design of a clinical trial in acute myeloid leukemia

enthalten in: Pharmaceutical Statistics | 2020

von Rufibach, K. | Heinzmann, D. | Monnet, A.

10

Integrating Phase 2 into Phase 3 based on an Intermediate Endpoint While Accounting for a Cure Proportion -- with an Application to the Design of a Clinical Trial in Acute Myeloid Leukemia

enthalten in: arXiv.org | 2019

von Rufibach, K. | Heinzmann, D. | Monnet, A.